Peter Rieckmann
Overview
Explore the profile of Peter Rieckmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
3414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gulde P, Vojta H, Schmidle S, Rieckmann P, Hermsdorfer J
J Neuroeng Rehabil
. 2025 Mar;
22(1):49.
PMID: 40045323
Background: Quantifying and monitoring the sensorimotor state of persons with neurological disease by means of wearables in everyday life has been shown to be a promising approach. To date, the...
2.
Gulde P, Vojta H, Schmidle S, Rieckmann P, Hermsdorfer J
Stroke
. 2023 Dec;
55(1):146-155.
PMID: 38037226
Background: The rehabilitation of upper limb sensorimotor performance after stroke requires the assessment of daily use, the identification of key levels of impairment, and monitoring the course of recovery. It...
3.
Amereller F, Schopohl J, Stormann S, Schilbach K, Bidlingmaier M, Fischer M, et al.
Case Rep Neurol
. 2023 Oct;
15(1):163-171.
PMID: 37901128
Although the prognosis in Guillain-Barré syndrome (GBS) is generally good, protracted and incomplete courses of recovery can be a heavy burden. Animal studies suggest growth hormone (GH) treatment could stimulate...
4.
Oreja-Guevara C, Potra S, Bauer B, Centonze D, Giambastiani M, Giovannoni G, et al.
Adv Ther
. 2023 Oct;
40(12):5131-5136.
PMID: 37812333
This is a summary of a previously published paper: Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. It describes a collaboration between...
5.
Gulde P, Vojta H, Schmidle S, Rieckmann P, Hermsdorfer J
J Neuroeng Rehabil
. 2023 Sep;
20(1):123.
PMID: 37735674
Background: Wearable technologies are currently clinically used to assess energy expenditure in a variety of populations, e.g., persons with multiple sclerosis or frail elderly. To date, going beyond physical activity,...
6.
Hassoun H, Almahdawi A, Jamal Al-Bajalan S, Sheaheed N, Kamil M, Saeed Ridha S, et al.
Heliyon
. 2023 Feb;
9(2):e13350.
PMID: 36816245
Background: Multiple sclerosis (MS) is often diagnosed in women of childbearing age (WCBA), with a mean age of onset of 30 years. Women with MS have long been cautioned to...
7.
Rieckmann P, Centonze D, Giovannoni G, Hua L, Oreja-Guevara C, Selchen D, et al.
Neurodegener Dis Manag
. 2022 Oct;
13(1):5-13.
PMID: 36278394
What Is This Summary About?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary...
8.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Jack D, et al.
Neurodegener Dis Manag
. 2022 Aug;
12(6):295-301.
PMID: 36017780
What Is This Summary About?: This is a summary of an article originally published in the journal . Cladribine tablets are approved for treating people with relapsing multiple sclerosis (shortened...
9.
Meuth S, Bayas A, Kallmann B, Linker R, Rieckmann P, Wattjes M, et al.
Expert Opin Pharmacother
. 2022 Aug;
23(13):1503-1510.
PMID: 35930260
Introduction: Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed for relapsing multiple sclerosis (RMS) since 2017. A full treatment course comprises two treatment cycles given 1...
10.
Rieckmann P, Ziemssen T, Penner I, Raji A, Wagner T, Richter J, et al.
Adv Ther
. 2022 Apr;
39(6):2749-2760.
PMID: 35428903
Introduction: Consistent treatment adherence is an important determinant of durable response in multiple sclerosis (MS). Published data indicate that adherence to > 80% of prescribed doses may be considered optimal....